Active substance
Diazepam
- SFDA 18
- US FDA 100
- Health Canada 8
- US price lines 16
- NHS prices 6
- WHO EML 3
- Safety 14
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DIAPAM 10MG/2ML SOL. FOR INJ./INF | 5 mg/ml | Solution for injection/infusion · Intramuscular and intravenous use | 10 Vial | SAR 23.85 | Generic · Prescription | MEDOCHEMIE LTD PHARMACEUTICAL INDUSTRY | Valid |
| VALIUM AMP 10MG-2ML | 5 mg/ml | Solution for injection · Intravenous use | 10 Ampoule | SAR 23.85 | Generic · Prescription | Atnahs Pharma UK Limited | Valid |
| VALIUM TAB 10 MG | 10 mg | Tablet · Oral use | 25 Blister | SAR 24.05 | NCE · Prescription | ROCHE | Valid |
| VALIUM TAB 2 MG | 2 mg | Tablet · Oral use | 30 Blister | SAR 11.00 | Generic · Prescription | ROCHE | Valid |
| VALIUM TAB 5MG | 5 mg | Tablet · Oral use | 25 Blister | SAR 16.80 | Generic · Prescription | Atnahs Pharma UK Limited | Valid |
| DIAZEPAM TAB 2 MG | 2 mg | Tablet · Oral use | 30 Blister | SAR 5.40 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| DIAZEPAM TAB 5 MG | 5 mg | Tablet · Oral use | 30 Blister | SAR 7.85 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| STESOLID 5MG RECTAL TUBE | 5 mg | Ointment · Rectal use | 4 Tube | SAR 26.20 | Generic · Prescription | ALPHARMA APS | Withdrawn by MAH · Not Marketed |
| STESOLID INJ 10 MG-2 ML | 5 mg/ml | Solution · Intravenous use | 5 Ampoule | SAR 10.90 | NCE · Prescription | ALPHARMA APS | Withdrawn by MAH · Not Marketed |
| STESOLID RECTAL TUBE 10 MG | 10 mg | Ointment · Rectal use | 4 Tube | SAR 32.25 | NCE · Prescription | ALPHARMA APS | Withdrawn by MAH · Not Marketed |
| STESOLID SUPP 5 MG | 5 mg | Suppository · Rectal use | 5 Blister | SAR 4.80 | Generic · Prescription | ALPHARMA APS | Withdrawn by MAH · Not Marketed |
| STESOLID SUPP. 10 MG | 10 mg | Suppository · Rectal use | 5 Blister | SAR 9.55 | Generic · Prescription | ALPHARMA APS | Withdrawn by MAH · Not Marketed |
| STESOLID SYRUP 0.4 MG-ML | 0.4 mg/ml | Syrup · Oral use | 1 Bottle | SAR 8.65 | NCE · Prescription | ALPHARMA APS | Withdrawn by MAH · Not Marketed |
| STESOLID TAB 2 MG | 2 mg | Tablet · Oral use | 25 Blister | SAR 4.70 | Generic · Prescription | ALPHARMA APS | Withdrawn by MAH · Not Marketed |
| STESOLID TAB. 5 MG | 5 mg | Tablet · Oral use | 25 Blister | SAR 9.10 | Generic · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
| VALINIL 2 | 2 mg | Tablet · Oral use | 30 Blister | SAR 4.75 | Generic · Prescription | THE NILE COMPANY FOR PHARMACEUTICALS AND CHEMICAL IND. | Withdrawn by MAH · Not Marketed |
| VALINIL 5 | 5 mg | Tablet · Oral use | 30 Blister | SAR 5.50 | Generic · Prescription | THE NILE COMPANY FOR PHARMACEUTICALS AND CHEMICAL IND. | Invalid · Not Marketed |
| VALIUM SYRUP 2 MG-5 ML | 0.4 mg/ml | Syrup · Oral use | 1 Bottle | SAR 16.60 | Generic · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE MANIA; ANESTHESIA; ANXIETY DISORDERS; BIPOLAR II DISORDER; HUNTINGTON'S DISEASE-TICS; MULTIPLE SCLEROSIS; SCHIZOPHRENIA; SPASTICITY; STATUS EPILEPTICUS; VERTIGO - MOTION SICKNESS; VERTIGO -BENIGN PAROXYSMAL POSITIONAL VERTIGO AND ACUTE VESTIBULAR NEURONITIS OR LABYRINTHITIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VALIUM | 2MG; 5MG; 10MG | tablet · oral | WAYLIS THERAP | Prescription | 15 Nov 1963 |
| DIAZEPAM | 10MG; 2MG; 5MG | tablet · oral | MYLAN | Prescription | 4 Sep 1985 |
| DIAZEPAM | 50MG/10ML (5MG/ML) | injectable · injection | HIKMA PHARMS | Prescription | 16 Dec 1985 |
| DIAZEPAM | 10MG/2ML (5MG/ML) | injectable · injection | HIKMA PHARMS | Prescription | 16 Dec 1985 |
| DIAZEPAM | 10MG; 2MG; 5MG | tablet · oral | NUVO PHARM | Prescription | 25 Feb 1986 |
| DIAZEPAM | 2MG | tablet · oral | IVAX SUB TEVA PHARMS | Prescription | 10 Dec 1986 |
| DIAZEPAM | 5MG | tablet · oral | IVAX SUB TEVA PHARMS | Prescription | 10 Dec 1986 |
| DIAZEPAM | 10MG | tablet · oral | IVAX SUB TEVA PHARMS | Prescription | 10 Dec 1986 |
| DIAZEPAM | 2MG | tablet · oral | DR REDDYS LABS SA | Prescription | 3 Feb 1987 |
| DIAZEPAM | 5MG | tablet · oral | DR REDDYS LABS SA | Prescription | 3 Feb 1987 |
| DIAZEPAM | 10MG | tablet · oral | DR REDDYS LABS SA | Prescription | 3 Feb 1987 |
| DIAZEPAM | 5MG/5ML | solution · oral | HIKMA PHARMS | Prescription | 3 Apr 1987 |
| DIAZEPAM INTENSOL | 5MG/ML | concentrate · oral | HIKMA PHARMS | Prescription | 3 Apr 1987 |
| DIAZEPAM | 50MG/10ML (5MG/ML) | injectable · injection | HOSPIRA | Prescription | 13 Oct 1987 |
| DIAZEPAM | 10MG/2ML (5MG/ML) | injectable · injection | HOSPIRA | Prescription | 20 Dec 1988 |
| DIASTAT | 2.5MG/0.5ML (5MG/ML) | gel · rectal | BAUSCH | Prescription | 29 Jul 1997 |
| DIASTAT ACUDIAL | 20MG/4ML (5MG/ML); 10MG/2ML (5MG/ML) | gel · rectal | BAUSCH | Prescription | 29 Jul 1997 |
| DIAZEPAM | 5MG/ML | concentrate · oral | CHARTWELL MOLECULAR | Prescription | 14 Apr 2014 |
| DIAZEPAM | 5MG/5ML | solution · oral | CHARTWELL MOLECULAR | Prescription | 24 Jun 2016 |
| DIAZEPAM | 10MG/2ML (5MG/ML) | injectable · injection | REGCON HOLDINGS | Prescription | 18 Mar 2019 |
| DIAZEPAM | 50MG/10ML (5MG/ML) | injectable · injection | REGCON HOLDINGS | Prescription | 26 Dec 2019 |
| VALTOCO | 5MG/SPRAY; 7.5MG/SPRAY; 10MG/SPRAY | spray · nasal | NEURELIS INC | Prescription | 10 Jan 2020 |
| DIAZEPAM | 10MG/2ML (5MG/ML) | injectable · injection | FRESENIUS KABI USA | Prescription | 10 Nov 2022 |
| DIAZEPAM | 10MG/2ML (5MG/ML); 20MG/4ML (5MG/ML) | gel · rectal | NOVEL LABS INC | Prescription | 30 May 2023 |
| DIAZEPAM | 2MG; 5MG; 10MG | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 14 Dec 2023 |
75 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| DIASTAT | 02238162 | 5 MG / 1 ML | GEL · RECTAL | BAUSCH HEALTH, CANADA INC. |
| DIASTAT | 02519070 | 10 MG / 2 ML | GEL · RECTAL | BAUSCH HEALTH, CANADA INC. |
| DIASTAT | 02519089 | 15 MG / 3 ML | GEL · RECTAL | BAUSCH HEALTH, CANADA INC. |
| DIAZEPAM | 00362158 | 5 MG | TABLET · ORAL | AA PHARMA INC |
| DIAZEPAM | 00405329 | 2 MG | TABLET · ORAL | AA PHARMA INC |
| DIAZEPAM | 00405337 | 10 MG | TABLET · ORAL | AA PHARMA INC |
| DIAZEPAM INJECTION USP | 00399728 | 5 MG / ML | SOLUTION · INTRAVENOUS; INTRAMUSCULAR | SANDOZ CANADA INCORPORATED |
| VALIUM | 00013285 | 5 MG | TABLET · ORAL | SEARCHLIGHT PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DIAZEPAM 10 MG RECTAL GEL | $208.71283 | per EA | 23 Sep 2026 |
| US NADAC | DIAZEPAM 10 MG RECTAL GEL (2PK) | $208.71283 | per EA | 23 Sep 2026 |
| US NADAC | DIAZEPAM 10 MG RECTAL GEL SYRG | $208.71283 | per EA | 23 Sep 2026 |
| US NADAC | DIAZEPAM 10 MG TABLET | $0.02828 | per EA | 23 Sep 2026 |
| US NADAC | DIAZEPAM 2 MG TABLET | $0.02123 | per EA | 23 Sep 2026 |
| US NADAC | DIAZEPAM 20 MG RECTAL GEL | $171.53691 | per EA | 23 Sep 2026 |
| US NADAC | DIAZEPAM 20 MG RECTAL GEL (2PK) | $171.53691 | per EA | 23 Sep 2026 |
| US NADAC | DIAZEPAM 20 MG RECTAL GEL SYRG | $171.53691 | per EA | 23 Sep 2026 |
| US NADAC | DIAZEPAM 25 MG/5 ML ORAL CONC | $1.06202 | per ML | 23 Sep 2026 |
| US NADAC | DIAZEPAM 5 MG TABLET | $0.02761 | per EA | 23 Sep 2026 |
| US NADAC | DIAZEPAM 5 MG/5 ML SOLUTION | $0.10708 | per ML | 23 Sep 2026 |
| US NADAC | DIAZEPAM 5 MG/ML ORAL CONC | $1.06202 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Diazepam 10mg tablets | £0.84 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Diazepam 10mg/2.5ml rectal solution tube | £8.78 | 5 tube | 1 Oct 2026 |
| NHS Drug Tariff | Diazepam 10mg/2ml solution for injection ampoules | £40.30 | 10 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Diazepam 2mg tablets | £0.73 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Diazepam 5mg tablets | £0.74 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Diazepam 5mg/2.5ml rectal solution tube | £5.85 | 5 tube | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 5.1.1. Antiseizure medicines · core
Therapeutic equivalent to lorazepam for Status epilepticus; Status epilepticus
Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system | Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube - 2.3. Medicines for other common symptoms in palliative care · core
Palliative care
Oral > Liquid: 2 mg per 5 mL | Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system | Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube | Parenteral > General injections > unspecified: 5 mg per mL (EML) | Oral > Solid > tablet: 5 mg (scored); 10 mg (scored); 2 mg (scored) (EMLc) - 24.3. Medicines for anxiety disorders · core
Anxiety
Oral > Solid: 5 mg (scored); 2 mg (scored)
Safety signals and safety-related labeling changes
- US FDA 24 Sep 2026 VALIUM — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 7 May 2026 PRAC signal: Miscarriage associated with in utero exposure to benzodiazepines (including fixed-dose combinations)
Action for MAH: update of the product information: No - EMA PRAC 7 May 2026 PRAC signal: Miscarriage associated with in utero exposure to benzodiazepines (including fixed-dose combinations)
Action for MAH: update of the product information: No - EMA PRAC 7 May 2026 PRAC signal: Miscarriage associated with in utero exposure to benzodiazepines (including fixed-dose combinations)
Action for MAH: update of the product information: No - EMA PRAC 7 May 2026 PRAC signal: Miscarriage associated with in utero exposure to benzodiazepines (including fixed-dose combinations)
Action for MAH: update of the product information: No - EMA PRAC 7 May 2026 PRAC signal: Miscarriage associated with in utero exposure to benzodiazepines (including fixed-dose combinations)
Action for MAH: update of the product information: No - EMA PRAC 7 May 2026 PRAC signal: Miscarriage associated with in utero exposure to benzodiazepines (including fixed-dose combinations)
Action for MAH: update of the product information: No - EMA PRAC 7 May 2026 PRAC signal: Miscarriage associated with in utero exposure to benzodiazepines (including fixed-dose combinations)
Action for MAH: update of the product information: No - EMA PRAC 7 May 2026 PRAC signal: Miscarriage associated with in utero exposure to benzodiazepines (including fixed-dose combinations)
Action for MAH: update of the product information: No - EMA PRAC 7 May 2026 PRAC signal: Miscarriage associated with in utero exposure to benzodiazepines (including fixed-dose combinations)
Action for MAH: update of the product information: No - US FDA 15 Apr 2025 VALTOCO — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Jan 2023 DIASTAT — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations - US FDA 13 Jan 2023 DIASTAT ACUDIAL — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Drug Interactions; Use in Specific Populations - US FDA 13 Jan 2023 DIAZEPAM — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Drug Interactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.